Ibrutinib Plus Lenalidomide and Rituximab Shows Promise in R/R MCL

(MedPage Today) — At December’s American Society of Hematology (ASH) virtual meeting, data from the PHILEMON phase II trial were presented, which evaluated a regimen of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory…
Leia Mais